 |
|
|
| |
Baseline and early on-treatment characteristics in HBeAg-positive patients with chronic hepatitis B infection achieving an early on-treatment response to pegylated interferon alfa-2a (40KD): interim results from the RGT study
|
| |
| |
Reported by Jules Levin
AASLD Nov 5-8 2011 SF
J.L. Hou,1 H. Ma,2 J. Sun,1 Q. Xie,3 Y. Xie,4 Y.T. Sun,5 H. Wang,6 G.F. Shi,7 M.B. Wan,8 J.Q. Niu,9 Q. Ning,10 Y.Y. Yu,11 M. Jiang12
1Hepatology Unit, Nanfang Hospital, Guangzhou, China; 2Liver Research Center, Beijing Friendship Hospital, Beijing, China; 3Department of Infectious Disease, Shanghai Ruijin Hospital, Shanghai, China; 4Liver Disease Department, Beijing DiTan Hospital, Beijing, China; 5Department of Infectious Disease, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China; 6Liver Disease Department, Peking University People's Hospital, Beijing, China; 7Department of Infectious Disease, Huashan Hospital affiliated to Fudan University, Shanghai, China; 8Department of Infectious Disease, Shanghai Changhai Hospital, Shanghai, China; 9Hepatology Unit, First Hospital of Jilin University, Changchun, China; 10Department of Infectious Disease, Wuhan Tongji Hospital, Tongji Medical College, Huazhong Technology University, Wuhan, China; 11Department of Infectious Disease, Peking University First Hospital, Beijing, China; 12formerly of Shanghai Roche Pharmaceuticals Co. Ltd, Shanghai, China
|
| |
|
|
|
|
|
